Hartnett Mary Elizabeth, Toth Cynthia Ann
Ophthalmic Surg Lasers Imaging Retina. 2019 Apr 1;50(4):228-234. doi: 10.3928/23258160-20190401-05.
Treatment of severe retinopathy of prematurity (ROP) has evolved over the last decade. This article reviews recent clinical trials and experimental evidence that supports clinical outcomes and observations, including the efficacy of anti-vascular endothelial growth factor (VEGF) agents in reducing the vascular activity of severe ROP, and the mechanisms behind recurrent stage 3 ROP and plus disease in some infants treated with anti-VEGF agents. Also discussed will be current imaging modalities that link experimental models of ROP with longitudinal human studies and which provide exciting future opportunities to enhance the understanding of pathophysiology of ROP and improve treatments. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:228-234.].
在过去十年中,早产儿视网膜病变(ROP)的治疗方法不断发展。本文回顾了近期支持临床结果和观察的临床试验及实验证据,包括抗血管内皮生长因子(VEGF)药物在降低重度ROP血管活性方面的疗效,以及接受抗VEGF药物治疗的部分婴儿出现复发性3期ROP和Plus病变背后的机制。还将讨论当前将ROP实验模型与纵向人体研究联系起来的成像方式,这些成像方式为加深对ROP病理生理学的理解和改进治疗方法提供了令人兴奋的未来机会。[《眼科手术、激光与视网膜成像》。2019年;50:228 - 234。]